Expert Guidance on MSI/MMR and the Role of Immune Checkpoint Inhibitors in GI Cancer

In this 2-hour, interactive CME-certified symposium, join our expert faculty panel for a case-based discussion on screening for MMR-deficiency/MSI-high status in GI cancers, the most relevant clinical data for immune checkpoint inhibitors, and a targeted review of ongoing clinical trials of checkpoint inhibitor therapies in patients with GI cancers.

Not an official event of the 2018 Gastrointestinal Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO or the Conquer Cancer Foundation.

Agenda

  • Screening for MMR Deficiency and MSI in GI Cancers
  • Efficacy and Safety Data for Immune Checkpoint Inhibitors in GI Cancers
  • Review of Immune-Related Adverse Events and Ongoing Clinical Trials of Immune Checkpoint Inhibitors in GI Cancers

Events

Date / Time
Event Details

Faculty

Program Director
John Marshall, MD

Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

Faculty
Tanios Bekaii-Saab, MD, FACP

Professor 
Mayo Clinic College of Medicine and Science
Co-Leader, GI Cancer Program
Mayo Clinic Cancer Center
Senior Associate Consultant
Mayo Clinic Arizona
Phoenix, Arizona

Faculty
Cathy Eng, MD

Associate Professor
Department of Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Faculty
Axel Grothey, MD

Professor, Oncology
Mayo Clinic
Rochester, Minnesota

Faculty
Manish Shah, MD

Bartlett Family Associate Professor of Gastrointestinal Oncology
Cheif,
Solid Tumor Services
Director,Gastrointestinal Oncology Program
Co-Director Center of Advanced Digestive Care
Weill Cornell Medical College
NewYork-Presbyterian Hospital
New York, New York

CME

Goal Statement
The goal of this activity is to improve the ability of clinicians to assess the microsatellite instability high phenotype in patients with gastrointestinal cancers to optimize and personalize their care.

Target Audience
This program is intended for oncologists, pathologists, and other healthcare providers who care for patients with gastrointestinal cancers.

Learning Objectives

  • Screen patients with advanced gastrointestinal cancers for microsatellite instability or mismatch repair deficiencies
  • Evaluate available and emerging biomarkers of response to identify patients with gastrointestinal cancers most likely to benefit from immune checkpoint inhibitor therapy
  • Plan treatment strategies for patients with MSI-H gastrointestinal cancers based on available data, treatment guidelines, and expert recommendations
  • Incorporate enrollment of appropriate patients on clinical trials investigating immune checkpoint inhibitor–based therapy as part of clinical care strategies for patients with gastrointestinal cancers
  • Identify and manage immune-related adverse events in patients receiving checkpoint inhibitor therapy

Accreditation

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Postgraduate Institute for Medicine designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.